



KEY FACTS in MULTIPLE MYELOMA



5-year relative survival rates for multiple myeloma from 1990-2014 increased more than four times faster than for other cancers.¹



Advances in Myeloma Treatments Continue to Improve the Relative Survival Rates for Patients²



36.8%*

Average Increase in Celgene R&D Investment

7.4%

Average Increase in Revlimid U.S. Price

Since 2006, Celgene's average annual increase in R&D investment is approximately **5x** the average annual price increase for Revlimid[®] (*lenalidomide*) capsules.³

* On a GAAP (Generally Accepted Accounting Principles) basis.

For prescribing information for Revlimid[®], including Boxed WARNINGS, please visit: <http://media.celgene.com/content/uploads/revlimid-pi.pdf>

Revlimid[®] is only available through a restricted distribution program, the Revlimid REMS[®] Program



In 2018, Celgene is supporting **206** global investigator-led trials and cooperative groups in multiple myeloma.⁴



4 of the 5 novel agents launched in multiple myeloma since 2013 have been approved for use in combination with a Celgene therapy.⁵

1. National Cancer Institute, SEER Cancer Statistics Review 1975-2015. Difference in 5-year relative survival between the 1990-1992 cohort and the 2007-2014 cohort calculated. Data on file at Celgene.
 2. Drawid A et al. Impact of Novel Therapies on Multiple Myeloma - Current and Future Outcomes. Poster presented at the 20th Congress of the European Haematology Association; Vienna, Austria, June 11-14, 2015.
 3. Internal data on Celgene R&D investment and Revlimid pricing.
 4. Internal data on investigator-led trials and COOPs.
 5. U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. Retrieved from: <http://wayback.archive-it.org/7993/20170111064250/> <http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm>.